Recently Introduced Products

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Potential Impact</th>
<th>Approx. Cost Per Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combivent Respimat</td>
<td>An Inhalation solution indicated for the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD)</td>
<td>$</td>
<td>$545.30</td>
</tr>
</tbody>
</table>

$: Est. drug plan expenditure increase of <1%* $$: Est. drug plan expenditure increase of 1-5%* $$$: Est. drug plan expenditure increase of >5%*

**Trintellix® – New Once Daily Antidepressant with a Unique Multi-Modal Mechanism of Action**

Trintellix® has a unique multimodal mode of action, which works through a combination of two mechanisms of action: receptor activity modulation and reuptake inhibition. Trintellix® is both an inhibitor of serotonin reuptake, mimics the effects, or blocks the receptors effect at serotonin. Serotonin receptors are responsible for such things like appetite, cognition, learning, memory, mood, perception, anxiety, sleep, etc.

In studies conducted, Trintellix® statistically significantly improved neurocognitive performance versus Cymbalta and decrease sexual dysfunction versus Cipralex. It also had better tolerability and lower withdrawal rates over Effexor XR. Although Trintellix has demonstrated increased efficacy in neurocognitive improvement in clinical trials, its only Health Canada approved indication is for the treatment of Major Depressive Disorder (MDD). Studies have shown, that in terms of depression, Trintellix’s efficacy is comparable to already available antidepressants.

MDD is a debilitating disease that can affect a person’s health and life. Depending on the severity and duration, MDD may become more serious, and potentially lead to suicide. Depression affects each person in different ways and symptoms vary from person to person. Generally, people with major depression usually experience extended periods of sadness, loneliness, despair, and they are often unable to find enjoyment in activities they once found pleasurable. MDD can cause problems with a person’s diet, sleep, work life, and ability to connect with others.

At present, clinicians use the DSM-IV criteria in order to diagnose MDD. Patients are diagnosed with MDD if they present with 5 of the 9 following criteria for at least two weeks: depressed mood or irritable, decreased interest of pleasure, significant weight change or change in appetite, change in sleep, and change in activity, fatigue or loss of energy, guilt/worthlessness, decreased concentration, or suicidality.

It is estimated that 3.9 million Canadians each year and approximately 1 in 10 will experience an episode of MDD during their lifetime.

MDD presents as multifaceted factors and symptoms, thus the treatment approach has to be patient specific for the best treatment outcome. At present, treatment guidelines indicate that medications (anti-depressants and mood stabilizing medications), psychotherapy, cognitive therapy, interpersonal therapy and peer support in individually or in combination should be tailored to each patient.

Although Trintellix® is effective in neurocognitive improvement; studies have shown that it is equally effective in the relief of major depressive disorder as currently available anti-depressants and mood stabilizers. Therefore, it is recommended that Trintellix® be placed under Special Authorization for ClaimSecure groups that subscribe to the Managed Formulary.

* Based on the Financial Impact Analysis per 100 000 lives covered © 2015 ClaimSecure Inc.
The Special Authorization process seeks to ensure that Trintellix® is used only in patients that have previously tried therapy with currently available anti-depressants. For Open Drug Formularies, Trintellix® will be fully covered.

*Based on the Financial Impact Analysis per 100,000 lives covered

If you require additional information about Trintellix®, please contact the Clinical Services Department, at (905) 949-2322 or 1-888-479-7587 ext. 2422.

Recommendation: Special Authorization

ClaimSecure reserves the right to amend in part or in its entirety stated special authorization clinical guidelines

References: